Ontario is joining several other provinces and territories by expanding the use of biosimilar drug treatments for Ontarians. Starting March 31, 2023, Ontario Drug Benefit (ODB) recipients who are on an originator biologic will begin to transition to a Health Canada approved biosimilar version of the drug at no cost.
Ontarians receiving coverage under the ODB program for Copaxone®, Enbrel®, Humalog®, Humira®, Lantus®, NovoRapid®, Remicade®, and Rituxan®, will be required to transition to the biosimilar version by December 29, 2023. During the transition period between March 31 and December 29, 2023, patients are encouraged to discuss a transition plan with their health care provider. Exemptions will be considered for patients in certain clinical circumstances on a case-by-case basis in consultation with their health care provider.
Read the full news release here:
https://news.ontario.ca/en/release/1002611/ontario-expanding-safe-use-of-biosimilars
CSA advocates for the broadest range of treatment options to be available for SpA patients. View our biosimilars position here